2026 has hit, and the industry appears to be undergoing an interesting structural shift. We’ve passed the post-pandemic correction and have entered something new: an era of reskilling. While we’re seeing resilient expansion in the global workforce, the standard pharma role is being replaced by hybrid, tech-heavy, and specialised positions.
Let’s take a look at what you need to know about the pharma career landscape this year:
The changing hiring market
We know that 2025 saw declines in some pharma hiring activity, and overall job postings declined in certain markets. While some departments are continuing to see cost-cutting and lean restructuring, certain growth pockets are exploding. We’re seeing a move away from traditional small-molecule roles towards biologics and vaccines. If your expertise lies in antibody design, regulatory science, or bioprocess engineering, you may be enjoying a hot zone of hiring demand, a trend we are seeing clearly within the Swiss biotech clusters.
Digital infiltration
One of the most significant trends this year is the erasure of the line between life sciences and big tech. We’re building discovery pipelines around artificial intelligence rather than simply just using it. For example, AI specialists for drug discovery and digital health analysts are increasingly in demand. In hubs like Basel and Zurich, the integration of Data-Scientists-as-Scientists is becoming the new gold standard.
Manufacturing is moving
Switzerland continues to be a primary destination for high-complexity, Pharma 4.0 manufacturing. We are seeing a huge global investment in physical infrastructure further afield. New facilities for advanced therapies are popping up all over the world, including major hubs in North America, Shanghai, and Singapore. This is all driving a surge in technical operations, quality assurance, and supply chain resilience.
Taking opportunities in the right locations
North America certainly remains dominant in research and development, but the Asia-Pacific region is growing in prominence for manufacturing and regulatory capacity. Meanwhile, Europe is doubling down on specialised innovation centres to remain competitive. Nowadays, career mobility often means looking towards these emerging global hubs. Additionally, companies are starting to invest more in reskilling and upskilling initiatives. This effectively helps to bridge talent gaps brought about by rapid technological adoption.
Adapt your talent
Pharma professionals of 2026 are looking very different to those of 2020. Now, employers are on the hunt for interdisciplinary talent – it’s no longer enough to understand the lab. Now, you have to be able to understand the data and the cloud-native tools, as well as the complex global regulatory web.
The job market is evolving. If you invest in upskilling, you may find 2026 to be your year of opportunity.
What do you think of the changing global pharma landscape? And are you seeing these shifts in your sector? Let’s discuss in the comments below!